levodopa and idazoxan
levodopa has been researched along with idazoxan in 16 studies
Research
Studies (16)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (18.75) | 18.2507 |
| 2000's | 7 (43.75) | 29.6817 |
| 2010's | 6 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Sickles, AE; Stehouwer, DJ; Taylor, LL; Van Hartesveldt, C | 1 |
| Brotchie, JM; Fox, SH | 1 |
| Brotchie, JM; Crossman, AR; Fox, SH; Henry, B; Peggs, D | 1 |
| Bédard, PJ; Doan, VD; Grondin, R; Hadj Tahar, A; Ladure, P | 1 |
| Iakovidou, E; Lees, AJ; Manson, AJ | 1 |
| Brotchie, JM; Crossman, AR; Fox, SH; Henry, B; Hill, MP; Peggs, D | 1 |
| Agid, Y; Arnulf, I; Bejjani, B; Bonnet, AM; Brefel-Courbon, C; Descombes, S; Fabre, N; Montastruc, JL; Peyro-Saint Paul, H; Rascol, O; Thalamas, C; Vidailhet, M | 1 |
| Colpaert, F; Domino, EF; Marien, M; Ni, L | 1 |
| Brotchie, JM; Fox, SH; Gomez-Ramirez, J; Johnston, TH; Lee, J | 1 |
| Buck, K; Ferger, B | 1 |
| Buck, K; Ferger, B; Voehringer, P | 1 |
| Barnum, CJ; Bhide, N; Bishop, C; Goldenberg, AA; Klioueva, A; Lindenbach, D; Surrena, MA; Tignor, S; Walters, H | 1 |
| Gerlach, M; Halley, P; Riederer, P; van den Buuse, M | 1 |
| Huang, C; Liu, J; Wang, HS; Wang, T; Wang, Y | 1 |
Reviews
1 review(s) available for levodopa and idazoxan
| Article | Year |
|---|---|
Quantitative assessment of dyskinesias in subhuman primates.
Topics: Adrenergic alpha-Antagonists; Animals; Anti-Anxiety Agents; Antiparkinson Agents; Diagnosis, Differential; Dronabinol; Dyskinesia, Drug-Induced; Haplorhini; Idazoxan; Levodopa; Primates; Severity of Illness Index | 1999 |
Trials
2 trial(s) available for levodopa and idazoxan
| Article | Year |
|---|---|
Idazoxan is ineffective for levodopa-induced dyskinesias in Parkinson's disease.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Adult; Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Idazoxan; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Treatment Failure | 2000 |
Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Idazoxan; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Pilot Projects | 2001 |
Other Studies
13 other study(ies) available for levodopa and idazoxan
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Noradrenergic alpha-1 and alpha-2 antagonists block L-dopa-induced air-stepping in neonatal rats.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Animals, Newborn; Dioxanes; Female; Idazoxan; Levodopa; Locomotion; Male; Norepinephrine; Prazosin; Rats; Rats, Sprague-Dawley; Stereotyped Behavior | 1994 |
The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic Antagonists; Animals; Antiparkinson Agents; Brain; Callithrix; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Drug Synergism; Dyskinesias; Female; Idazoxan; Levodopa; Male; Receptors, Adrenergic, alpha-2; Time Factors; Yohimbine | 1999 |
Noradrenoceptor antagonism with idazoxan improves L-dopa-induced dyskinesias in MPTP monkeys.
Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; gamma-Aminobutyric Acid; Idazoxan; Levodopa; Macaca fascicularis; Motor Activity; MPTP Poisoning; Norepinephrine; Parkinson Disease | 2000 |
Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Apomorphine; Callithrix; Corpus Striatum; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Globus Pallidus; Idazoxan; Levodopa; Male; Neurologic Examination; Neurons; Norepinephrine; Substantia Nigra | 2001 |
Effects of (+/-)-idazoxan alone and in combination with L-DOPA methyl ester in MPTP-induced hemiparkinsonian monkeys.
Topics: Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Idazoxan; Levodopa; Macaca nemestrina; Parkinson Disease, Secondary; Time Factors | 2003 |
A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
Topics: Adrenergic alpha-Antagonists; Adrenergic Uptake Inhibitors; Amantadine; Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Dizocilpine Maleate; Dopamine Agents; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Haloperidol; Idazoxan; Levodopa; Male; Motor Activity; Parkinson Disease; Rats; Rats, Sprague-Dawley; Reserpine | 2005 |
The selective alpha1 adrenoceptor antagonist HEAT reduces L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Antiparkinson Agents; Brain; Cerebrospinal Fluid; Disease Models, Animal; Dyskinesia, Drug-Induced; Idazoxan; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Plasma; Propranolol; Random Allocation; Rats; Rats, Wistar; Receptors, Adrenergic, alpha-1; Tetralones | 2010 |
The alpha(2) adrenoceptor antagonist idazoxan alleviates L-DOPA-induced dyskinesia by reduction of striatal dopamine levels: an in vivo microdialysis study in 6-hydroxydopamine-lesioned rats.
Topics: Adrenergic Agents; Adrenergic alpha-Antagonists; Analysis of Variance; Animals; Antiparkinson Agents; Chromatography, High Pressure Liquid; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Idazoxan; Levodopa; Male; Microdialysis; Neurotoxicity Syndromes; Oxidopamine; Rats; Rats, Wistar; Tandem Mass Spectrometry | 2010 |
Effects of noradrenergic denervation on L-DOPA-induced dyskinesia and its treatment by α- and β-adrenergic receptor antagonists in hemiparkinsonian rats.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adrenergic Neurons; Animals; Behavior, Animal; Corpus Striatum; Desipramine; Disease Models, Animal; Dyskinesia, Drug-Induced; Hippocampus; Idazoxan; Levodopa; Male; Molecular Targeted Therapy; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Propranolol; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Sympathectomy, Chemical | 2012 |
The effect of piribedil on L-DOPA-induced dyskinesias in a rat model of Parkinson's disease: differential role of α(2) adrenergic mechanisms.
Topics: Adrenergic Agents; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Animals; Antiparkinson Agents; Benserazide; Clonidine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesia, Drug-Induced; Dystonia; Facial Asymmetry; Idazoxan; Levodopa; Locomotion; Oxidopamine; Parkinson Disease; Piribedil; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2; Statistics, Nonparametric; Upper Extremity | 2013 |
L-DOPA-induced dyskinesia in a rat model of Parkinson's disease is associated with the fluctuational release of norepinephrine in the sensorimotor striatum.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Benzylamines; Chromatography, High Pressure Liquid; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Idazoxan; Levodopa; Male; Microdialysis; Neurotransmitter Agents; Norepinephrine; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Time Factors; Tyrosine 3-Monooxygenase | 2014 |